| Balance Sheets | 2025-08-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 78,438 | |||
| Marketable securities | 350,391 | |||
| Prepaid expenses and other current assets | 11,774 | |||
| Total current assets | 440,603 | |||
| Operating lease right-of-use assets | 53,028 | |||
| Property and equipment, net | 20,498 | |||
| Restricted cash | 968 | |||
| Other assets | 7,375 | |||
| Total assets | 522,472 | |||
| Accounts payable | 8,609 | |||
| Accrued expenses and other current liabilities | 43,957 | |||
| Operating lease liabilities, current | 3,791 | |||
| Deferred revenue, current | 25,993 | |||
| Total current liabilities | 82,350 | |||
| Operating lease liabilities, net of current portion | 52,695 | |||
| Deferred revenue, net of current portion | 15,175 | |||
| Total liabilities | 150,220 | |||
| Common stock, 0.001 par value 500,000,000 shares authorized as of august31, 2025 and november30, 2024 76,872,686 and 75,870,718 shares issued and outstanding as of august31, 2025 and november30, 2024, respectively | 77 | |||
| Additional paid-in capital | 1,297,061 | |||
| Accumulated other comprehensive income | 119 | |||
| Accumulated deficit | -925,005 | |||
| Total stockholders equity | 372,252 | |||
| Total liabilities and stockholders equity | 522,472 | |||
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)